Competitor Analysis: Interferon

Date: April 1, 2013
Pages: 89
Price:
US$ 590.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CEB3CB599B6EN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Interferon
Product description

The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other infectious diseases, cancer and multiple sclerosis, respectively. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products and projects. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. INTERFERON ALPHA, BETA AND OTHER SUB-TYPES

a) INTERFERON alpha
  Interferon alpha sales 2012 of branded products in regulated markets
  1st generation Interferon alpha-2a in regulated markets
  1st generation Interferon alpha-2a in non-regulated markets
  Next generation Interferon alpha-2a in regulated markets
  Next generation Interferon alpha-2a in non-regulated markets and biosimilars
  1st generation Interferon alpha-2b in regulated markets
  1st generation Interferon alpha-2b in non-regulated markets and biosimilars
  Next generation Interferon alpha-2b in regulated markets
  Next generation Interferon alpha-2b in non-regulated markets and biosimilars
  Other Interferon alpha sub-types
  Interferon alpha with not specified sub-type – 1/2
  Purified natural human interferon alpha
b) Consensus INTERFERONs
c) INTERFERON beta
  Interferon beta sales 2012 of branded products in regulated markets
  1st generation Interferon beta-1a in regulated markets
  1st generation Interferon beta-1a in non-regulated markets and biosimilars
  1st generation Interferon beta-1b in regulated markets
  1st generation Interferon beta-1b in non-regulated markets and biosimilars
  1st generation Interferon beta with not disclosed sub-type
  Next generation Interferon beta in regulated markets
  Purified natural human interferon beta
d) INTERFERON gamma
e) Other INTERFERONs

2. CORPORATE INTERFERON PRODUCT PORTFOLIOS AND R&D PIPELINES

Ask Your Question

Competitor Analysis: Interferon
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: